ArticleThe mental health clinician2017
Review of cariprazine in management of psychiatric illness.
Article in The mental health clinician, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Physical illness in schizophrenia and the role of tolerability in antipsychotic selection: an expert consensus with a focus on cariprazine.Annals of general psychiatry · 2025Review
- Role of Serotonergic System in Regulating Brain Tumor-Associated Neuroinflammatory Responses.Methods in molecular biology (Clifton, N.J.) · 2024Article
- A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia.Frontiers in psychiatry · 2024Review
- Seventy Years of Antipsychotic Development: A Critical Review.Biomedicines · 2023Review
- Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up.Frontiers in psychiatry · 2023Article
- Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine.Frontiers in pharmacology · 2023Article
- Evaluation of the Effect of Cariprazine on Memory and Cognition in Experimental Rodent Models.International journal of environmental research and public health · 2022Article
- Cardiometabolic outcomes among schizophrenia patients using antipsychotics: the impact of high weight gain risk vs low weight gain risk treatment.BMC psychiatry · 2022Observational
- Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics.RSC advances · 2021Article
- A case series of serious and unexpected adverse drug reactions under treatment with cariprazine.Clinical case reports · 2021Article
- A study of the structure-affinity relationship in SYA16263; is a DBioorganic & medicinal chemistry · 2021Article
- Cariprazine in Three Special Different Areas: A Real-World Experience.Neuropsychiatric disease and treatment · 2021Article
- Cariprazine Use in Early Psychosis: Three Case Reports.Frontiers in psychiatry · 2021Article
- Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience.Neuropsychiatric disease and treatment · 2021Article
- Maternal cariprazine exposure inhibits embryonic and postnatal brain cholesterol biosynthesis.Molecular psychiatry · 2020Article
- DJournal of medicinal chemistry · 2019Article
- Multi-Target Approach for Drug Discovery against Schizophrenia.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia and bipolar disorder are severe and debilitating psychiatric disorders. Despite the availability of numerous antipsychotic drugs, many patients still experience poor outcomes and treatment-limiting adverse side effects. Cariprazine is a novel antipsychotic with unique pharmacodynamic and pharmacokinetic properties. It is both a dopamine type 2 and dopamine type 3 partial agonist with 2 equipotent metabolites, desmethyl cariprazine and didesmethyl cariprazine, of which didesmethyl cariprazine has a half-life of 1 to 3 weeks. The objective of this article is to review the literature regarding efficacy and tolerability of cariprazine in the management of psychiatric disorders to determine its current place in therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.